Serveur d'exploration Chloroquine

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Overexpression of MiR-452-5p in hepatocellular carcinoma tissues and its prospective signaling pathways

Identifieur interne : 000362 ( Pmc/Curation ); précédent : 000361; suivant : 000363

Overexpression of MiR-452-5p in hepatocellular carcinoma tissues and its prospective signaling pathways

Auteurs : Min-Hua Rong [République populaire de Chine] ; Kai-Teng Cai [République populaire de Chine] ; Hui-Ping Lu [République populaire de Chine] ; Yi-Nan Guo [République populaire de Chine] ; Xiong-Yan Huang [République populaire de Chine] ; Zhan-Hui Zhu [République populaire de Chine] ; Wei Tang [République populaire de Chine] ; Su-Ning Huang [République populaire de Chine]

Source :

RBID : PMC:6949781

Abstract

Background: The implication of miR-452-5p and its prospective machinery in hepatocellular carcinoma (HCC) remains largely unknown. For this reason, this study aimed to inspect the clinical implication of miR-452-5p expression in HCC tissues with multiple detection approaches, to analyze its potential function via in silico methods, and to validate this using a dual-luciferase reporter assay. Methods: The assessment of the expression level of miR-452-5p in HCC was conducted via four methods: 1) in-house real-time quantitative PCR (RT-qPCR), 2) miRNA-sequencing (miRNA-seq) from The Cancer Genome Atlas (TCGA), 3) miRNA microarrays from the Gene Expression Omnibus (GEO), and 4) comprehensive meta-analyses calculating the standard mean difference (SMD) and summary of receiver operator characteristic (sROC). Following the target prediction, one of the potential targets of miR-452-5p was validated through a dual-luciferase reporter assay. Results: MiR-452-5p was consistently elevated in HCC tissues via various detection methods, including in-house RT-qPCR, miRNA-seq, and miRNA microarrays. The final SMD was 0.842 for 820 cases of HCC samples. Simultaneously, the area under curve (AUC) of the sROC was 0.80 (0.76-0.83). The 1,135 predicted targets of miR-452-5p were enriched in the pathways of cytokine-cytokine receptor interaction, carbon metabolism, and complement and coagulation cascades. Among these predicted targets, CDKN1B was verified to be a real target of miR-452-5p. Conclusion: The overexpression of miR-452-5p may play a pivotal role in the carcinogenesis of HCC via targeting multiple signaling pathways and genes. The function and molecular machinery of miR-452-5p in HCC requires further in-depth exploration.


Url:
PubMed: 31933800
PubMed Central: 6949781

Links toward previous steps (curation, corpus...)


Links to Exploration step

PMC:6949781

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Overexpression of MiR-452-5p in hepatocellular carcinoma tissues and its prospective signaling pathways</title>
<author>
<name sortKey="Rong, Min Hua" sort="Rong, Min Hua" uniqKey="Rong M" first="Min-Hua" last="Rong">Min-Hua Rong</name>
<affiliation wicri:level="1">
<nlm:aff id="au1">
<institution>Research Department, Affiliated Cancer Hospital, Guangxi Medical University</institution>
<addr-line>71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region, P. R. China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Cai, Kai Teng" sort="Cai, Kai Teng" uniqKey="Cai K" first="Kai-Teng" last="Cai">Kai-Teng Cai</name>
<affiliation wicri:level="1">
<nlm:aff id="au1">
<institution>Research Department, Affiliated Cancer Hospital, Guangxi Medical University</institution>
<addr-line>71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region, P. R. China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Lu, Hui Ping" sort="Lu, Hui Ping" uniqKey="Lu H" first="Hui-Ping" last="Lu">Hui-Ping Lu</name>
<affiliation wicri:level="1">
<nlm:aff id="au2">
<institution>Department of Pathology, First Affiliated Hospital of Guangxi Medical University</institution>
<addr-line>Nanning 530021, Guangxi Zhuang Autonomous Region, P. R. China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Nanning 530021, Guangxi Zhuang Autonomous Region</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Guo, Yi Nan" sort="Guo, Yi Nan" uniqKey="Guo Y" first="Yi-Nan" last="Guo">Yi-Nan Guo</name>
<affiliation wicri:level="1">
<nlm:aff id="au2">
<institution>Department of Pathology, First Affiliated Hospital of Guangxi Medical University</institution>
<addr-line>Nanning 530021, Guangxi Zhuang Autonomous Region, P. R. China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Nanning 530021, Guangxi Zhuang Autonomous Region</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Huang, Xiong Yan" sort="Huang, Xiong Yan" uniqKey="Huang X" first="Xiong-Yan" last="Huang">Xiong-Yan Huang</name>
<affiliation wicri:level="1">
<nlm:aff id="au2">
<institution>Department of Pathology, First Affiliated Hospital of Guangxi Medical University</institution>
<addr-line>Nanning 530021, Guangxi Zhuang Autonomous Region, P. R. China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Nanning 530021, Guangxi Zhuang Autonomous Region</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Zhu, Zhan Hui" sort="Zhu, Zhan Hui" uniqKey="Zhu Z" first="Zhan-Hui" last="Zhu">Zhan-Hui Zhu</name>
<affiliation wicri:level="1">
<nlm:aff id="au1">
<institution>Research Department, Affiliated Cancer Hospital, Guangxi Medical University</institution>
<addr-line>71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region, P. R. China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Tang, Wei" sort="Tang, Wei" uniqKey="Tang W" first="Wei" last="Tang">Wei Tang</name>
<affiliation wicri:level="1">
<nlm:aff id="au3">
<institution>Department of Breast Surgery, Affiliated Cancer Hospital, Guangxi Medical University</institution>
<addr-line>71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region, P. R. China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Huang, Su Ning" sort="Huang, Su Ning" uniqKey="Huang S" first="Su-Ning" last="Huang">Su-Ning Huang</name>
<affiliation wicri:level="1">
<nlm:aff id="au4">
<institution>Department of Radiotherapy, Affiliated Cancer Hospital, Guangxi Medical University</institution>
<addr-line>71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region, P. R. China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region</wicri:regionArea>
</affiliation>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PMC</idno>
<idno type="pmid">31933800</idno>
<idno type="pmc">6949781</idno>
<idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6949781</idno>
<idno type="RBID">PMC:6949781</idno>
<date when="2019">2019</date>
<idno type="wicri:Area/Pmc/Corpus">000362</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000362</idno>
<idno type="wicri:Area/Pmc/Curation">000362</idno>
<idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000362</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en" level="a" type="main">Overexpression of MiR-452-5p in hepatocellular carcinoma tissues and its prospective signaling pathways</title>
<author>
<name sortKey="Rong, Min Hua" sort="Rong, Min Hua" uniqKey="Rong M" first="Min-Hua" last="Rong">Min-Hua Rong</name>
<affiliation wicri:level="1">
<nlm:aff id="au1">
<institution>Research Department, Affiliated Cancer Hospital, Guangxi Medical University</institution>
<addr-line>71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region, P. R. China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Cai, Kai Teng" sort="Cai, Kai Teng" uniqKey="Cai K" first="Kai-Teng" last="Cai">Kai-Teng Cai</name>
<affiliation wicri:level="1">
<nlm:aff id="au1">
<institution>Research Department, Affiliated Cancer Hospital, Guangxi Medical University</institution>
<addr-line>71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region, P. R. China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Lu, Hui Ping" sort="Lu, Hui Ping" uniqKey="Lu H" first="Hui-Ping" last="Lu">Hui-Ping Lu</name>
<affiliation wicri:level="1">
<nlm:aff id="au2">
<institution>Department of Pathology, First Affiliated Hospital of Guangxi Medical University</institution>
<addr-line>Nanning 530021, Guangxi Zhuang Autonomous Region, P. R. China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Nanning 530021, Guangxi Zhuang Autonomous Region</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Guo, Yi Nan" sort="Guo, Yi Nan" uniqKey="Guo Y" first="Yi-Nan" last="Guo">Yi-Nan Guo</name>
<affiliation wicri:level="1">
<nlm:aff id="au2">
<institution>Department of Pathology, First Affiliated Hospital of Guangxi Medical University</institution>
<addr-line>Nanning 530021, Guangxi Zhuang Autonomous Region, P. R. China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Nanning 530021, Guangxi Zhuang Autonomous Region</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Huang, Xiong Yan" sort="Huang, Xiong Yan" uniqKey="Huang X" first="Xiong-Yan" last="Huang">Xiong-Yan Huang</name>
<affiliation wicri:level="1">
<nlm:aff id="au2">
<institution>Department of Pathology, First Affiliated Hospital of Guangxi Medical University</institution>
<addr-line>Nanning 530021, Guangxi Zhuang Autonomous Region, P. R. China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>Nanning 530021, Guangxi Zhuang Autonomous Region</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Zhu, Zhan Hui" sort="Zhu, Zhan Hui" uniqKey="Zhu Z" first="Zhan-Hui" last="Zhu">Zhan-Hui Zhu</name>
<affiliation wicri:level="1">
<nlm:aff id="au1">
<institution>Research Department, Affiliated Cancer Hospital, Guangxi Medical University</institution>
<addr-line>71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region, P. R. China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Tang, Wei" sort="Tang, Wei" uniqKey="Tang W" first="Wei" last="Tang">Wei Tang</name>
<affiliation wicri:level="1">
<nlm:aff id="au3">
<institution>Department of Breast Surgery, Affiliated Cancer Hospital, Guangxi Medical University</institution>
<addr-line>71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region, P. R. China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region</wicri:regionArea>
</affiliation>
</author>
<author>
<name sortKey="Huang, Su Ning" sort="Huang, Su Ning" uniqKey="Huang S" first="Su-Ning" last="Huang">Su-Ning Huang</name>
<affiliation wicri:level="1">
<nlm:aff id="au4">
<institution>Department of Radiotherapy, Affiliated Cancer Hospital, Guangxi Medical University</institution>
<addr-line>71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region, P. R. China</addr-line>
</nlm:aff>
<country xml:lang="fr">République populaire de Chine</country>
<wicri:regionArea>71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region</wicri:regionArea>
</affiliation>
</author>
</analytic>
<series>
<title level="j">International Journal of Clinical and Experimental Pathology</title>
<idno type="eISSN">1936-2625</idno>
<imprint>
<date when="2019">2019</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass></textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">
<p>Background: The implication of miR-452-5p and its prospective machinery in hepatocellular carcinoma (HCC) remains largely unknown. For this reason, this study aimed to inspect the clinical implication of miR-452-5p expression in HCC tissues with multiple detection approaches, to analyze its potential function via
<italic>in silico</italic>
methods, and to validate this using a dual-luciferase reporter assay. Methods: The assessment of the expression level of miR-452-5p in HCC was conducted via four methods: 1) in-house real-time quantitative PCR (RT-qPCR), 2) miRNA-sequencing (miRNA-seq) from The Cancer Genome Atlas (TCGA), 3) miRNA microarrays from the Gene Expression Omnibus (GEO), and 4) comprehensive meta-analyses calculating the standard mean difference (SMD) and summary of receiver operator characteristic (sROC). Following the target prediction, one of the potential targets of miR-452-5p was validated through a dual-luciferase reporter assay. Results: MiR-452-5p was consistently elevated in HCC tissues via various detection methods, including in-house RT-qPCR, miRNA-seq, and miRNA microarrays. The final SMD was 0.842 for 820 cases of HCC samples. Simultaneously, the area under curve (AUC) of the sROC was 0.80 (0.76-0.83). The 1,135 predicted targets of miR-452-5p were enriched in the pathways of cytokine-cytokine receptor interaction, carbon metabolism, and complement and coagulation cascades. Among these predicted targets, CDKN1B was verified to be a real target of miR-452-5p. Conclusion: The overexpression of miR-452-5p may play a pivotal role in the carcinogenesis of HCC via targeting multiple signaling pathways and genes. The function and molecular machinery of miR-452-5p in HCC requires further in-depth exploration.</p>
</div>
</front>
</TEI>
<pmc article-type="research-article">
<pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Int J Clin Exp Pathol</journal-id>
<journal-id journal-id-type="iso-abbrev">Int J Clin Exp Pathol</journal-id>
<journal-id journal-id-type="publisher-id">ijcep</journal-id>
<journal-title-group>
<journal-title>International Journal of Clinical and Experimental Pathology</journal-title>
</journal-title-group>
<issn pub-type="epub">1936-2625</issn>
<publisher>
<publisher-name>e-Century Publishing Corporation</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">31933800</article-id>
<article-id pub-id-type="pmc">6949781</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Overexpression of MiR-452-5p in hepatocellular carcinoma tissues and its prospective signaling pathways</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Rong</surname>
<given-names>Min-Hua</given-names>
</name>
<xref ref-type="aff" rid="au1">1</xref>
<xref ref-type="author-notes" rid="fn1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Cai</surname>
<given-names>Kai-Teng</given-names>
</name>
<xref ref-type="aff" rid="au1">1</xref>
<xref ref-type="author-notes" rid="fn1">*</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Lu</surname>
<given-names>Hui-Ping</given-names>
</name>
<xref ref-type="aff" rid="au2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Guo</surname>
<given-names>Yi-Nan</given-names>
</name>
<xref ref-type="aff" rid="au2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Xiong-Yan</given-names>
</name>
<xref ref-type="aff" rid="au2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhu</surname>
<given-names>Zhan-Hui</given-names>
</name>
<xref ref-type="aff" rid="au1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tang</surname>
<given-names>Wei</given-names>
</name>
<xref ref-type="aff" rid="au3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Huang</surname>
<given-names>Su-Ning</given-names>
</name>
<xref ref-type="aff" rid="au4">4</xref>
</contrib>
<aff id="au1">
<label>1</label>
<institution>Research Department, Affiliated Cancer Hospital, Guangxi Medical University</institution>
<addr-line>71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region, P. R. China</addr-line>
</aff>
<aff id="au2">
<label>2</label>
<institution>Department of Pathology, First Affiliated Hospital of Guangxi Medical University</institution>
<addr-line>Nanning 530021, Guangxi Zhuang Autonomous Region, P. R. China</addr-line>
</aff>
<aff id="au3">
<label>3</label>
<institution>Department of Breast Surgery, Affiliated Cancer Hospital, Guangxi Medical University</institution>
<addr-line>71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region, P. R. China</addr-line>
</aff>
<aff id="au4">
<label>4</label>
<institution>Department of Radiotherapy, Affiliated Cancer Hospital, Guangxi Medical University</institution>
<addr-line>71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region, P. R. China</addr-line>
</aff>
</contrib-group>
<author-notes>
<corresp>
<bold>Address correspondence to:</bold>
Su-Ning Huang, Department of Radiotherapy, Affiliated Cancer Hospital, Guangxi Medical University, 71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region, P.R. China. E-mail:
<email>huangsuning2000@163.com</email>
; Wei Tang, Department of Breast Surgery, Affiliated Cancer Hospital, Guangxi Medical University, 71 Hedi Road, Nanning 530021, Guangxi Zhuang Autonomous Region, P.R. China. E-mail:
<email>21805195@qq.com</email>
</corresp>
<fn id="fn1">
<label>*</label>
<p>Equal contributors and co-first authors.</p>
</fn>
</author-notes>
<pub-date pub-type="collection">
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>01</day>
<month>11</month>
<year>2019</year>
</pub-date>
<volume>12</volume>
<issue>11</issue>
<fpage>4041</fpage>
<lpage>4056</lpage>
<history>
<date date-type="received">
<day>09</day>
<month>5</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>24</day>
<month>9</month>
<year>2019</year>
</date>
</history>
<permissions>
<copyright-statement>IJCEP Copyright © 2019</copyright-statement>
<copyright-year>2019</copyright-year>
</permissions>
<abstract>
<p>Background: The implication of miR-452-5p and its prospective machinery in hepatocellular carcinoma (HCC) remains largely unknown. For this reason, this study aimed to inspect the clinical implication of miR-452-5p expression in HCC tissues with multiple detection approaches, to analyze its potential function via
<italic>in silico</italic>
methods, and to validate this using a dual-luciferase reporter assay. Methods: The assessment of the expression level of miR-452-5p in HCC was conducted via four methods: 1) in-house real-time quantitative PCR (RT-qPCR), 2) miRNA-sequencing (miRNA-seq) from The Cancer Genome Atlas (TCGA), 3) miRNA microarrays from the Gene Expression Omnibus (GEO), and 4) comprehensive meta-analyses calculating the standard mean difference (SMD) and summary of receiver operator characteristic (sROC). Following the target prediction, one of the potential targets of miR-452-5p was validated through a dual-luciferase reporter assay. Results: MiR-452-5p was consistently elevated in HCC tissues via various detection methods, including in-house RT-qPCR, miRNA-seq, and miRNA microarrays. The final SMD was 0.842 for 820 cases of HCC samples. Simultaneously, the area under curve (AUC) of the sROC was 0.80 (0.76-0.83). The 1,135 predicted targets of miR-452-5p were enriched in the pathways of cytokine-cytokine receptor interaction, carbon metabolism, and complement and coagulation cascades. Among these predicted targets, CDKN1B was verified to be a real target of miR-452-5p. Conclusion: The overexpression of miR-452-5p may play a pivotal role in the carcinogenesis of HCC via targeting multiple signaling pathways and genes. The function and molecular machinery of miR-452-5p in HCC requires further in-depth exploration.</p>
</abstract>
<kwd-group>
<kwd>MiR-452-5p</kwd>
<kwd>CDKN1B</kwd>
<kwd>Hepatocellular carcinoma (HCC)</kwd>
<kwd>signaling pathways</kwd>
</kwd-group>
</article-meta>
</front>
</pmc>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Pmc/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000362 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd -nk 000362 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    ChloroquineV1
   |flux=    Pmc
   |étape=   Curation
   |type=    RBID
   |clé=     PMC:6949781
   |texte=   Overexpression of MiR-452-5p in hepatocellular carcinoma tissues and its prospective signaling pathways
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Curation/RBID.i   -Sk "pubmed:31933800" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a ChloroquineV1 

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Wed Mar 25 22:43:59 2020. Site generation: Sun Jan 31 12:44:45 2021